← All trials
NCT01114308
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2010
- Primary completion
- May 31, 2011
- Completion date
- May 31, 2011
- First posted
- May 3, 2010
- Last posted
- Dec 31, 2018
- Enrollment
- 287
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Titan PharmaceuticalsLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- Titan PharmaceuticalsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.